Michael B. Bolger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michael B. Bolger has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Balaji Agoram
USC School of Pharmacy, Department of Pharmaceutical Sciences, 1985 Zonal Ave. PSC 700, Los Angeles, CA 90089-9121, USA
1 shared publication- Boyd Steere
Eli Lilly and Company, Indianapolis, Indiana, USA
1 shared publication - Eric J. Martin
Novartis (United States)
1 shared publication - Ian S. Haworth
University of Southern California
1 shared publication - Mauricio A. García
Departamento de Farmacia, Escuela de Química y Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago, 7820436, Chile
1 shared publication - Pankaj R. Daga
Novartis Institute of Biomedical Research , Emeryville , California 94608 , United States
1 shared publication
Latest Publications
- 1 January 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (1) , 262-273
Predicting Pharmacokinetics of Multisource Acyclovir Oral Products Through Physiologically Based Biopharmaceutics Modeling
- 1 January 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (1) , 262-273
Predicting Pharmacokinetics of Multisource Acyclovir Oral Products Through Physiologically Based Biopharmaceutics Modeling
- 16 January 2018
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 15 (3) , 821-830
Physiologically Based Pharmacokinetic Modeling in Lead Optimization. 1. Evaluation and Adaptation of GastroPlus To Predict Bioavailability of Medchem Series
When medicinal chemists need to improve bioavailability (%F) within a chemical series during lead optimization, they synthesize new series members with systematically modified properties mainly by following experience and general rules of thumb. More quantitative models that predict %F of proposed compounds from chemical structure alone have proven elusive. Global empirical %F quantitative structure-property (QSPR) models perform poorly and projects have too little data to train local %F QSPR models. Mechanistic oral absorption and physiologically-based pharmacokinetic (PBPK) models simulate the dissolution, absorption, systemic distribution, and clearance of a drug in preclinical species and humans. Attempts to build global PBPK models based purely on calculated inputs have not achieved the loc). All inputs are subsequently computed from structure alone, so the models can be applied in advance of synthesis. Training CLloc on the first 15 – 18 rat %F measurements gave adequate predictions, with clear improvements up to about 30 measurements, and incremental improvements beyond that.
- 16 January 2018
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 15 (3) , 821-830
Physiologically Based Pharmacokinetic Modeling in Lead Optimization. 1. Evaluation and Adaptation of GastroPlus To Predict Bioavailability of Medchem Series
When medicinal chemists need to improve bioavailability (%F) within a chemical series during lead optimization, they synthesize new series members with systematically modified properties mainly by following experience and general rules of thumb. More quantitative models that predict %F of proposed compounds from chemical structure alone have proven elusive. Global empirical %F quantitative structure-property (QSPR) models perform poorly and projects have too little data to train local %F QSPR models. Mechanistic oral absorption and physiologically-based pharmacokinetic (PBPK) models simulate the dissolution, absorption, systemic distribution, and clearance of a drug in preclinical species and humans. Attempts to build global PBPK models based purely on calculated inputs have not achieved the loc). All inputs are subsequently computed from structure alone, so the models can be applied in advance of synthesis. Training CLloc on the first 15 – 18 rat %F measurements gave adequate predictions, with clear improvements up to about 30 measurements, and incremental improvements beyond that.